Since its clinical introduction in May 2011, prostate-specific membrane antigen (PSMA)-PET/computed tomography has quickly gained worldwide recognition as a significant breakthrough in prostate cancer diagnostics. In the meantime, several new PSMA radioligands for PET imaging have been introduced into routine clinical practice. This article aims to introduce the most commonly used tracers and their key areas of application.
PET clinics. 2024 May 02 [Epub ahead of print]
Ian L Alberts, Robert Seifert, Rudolf A Werner, Steven P Rowe, Ali Afshar-Oromieh
Molecular Imaging and Therapy, BC Cancer - Vancouver, 600 West 10th Avenue, Vancouver, British Columbia V5Z 1H5, Canada., University Clinic for Nuclear Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland., Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstr. 6, 97080 Würzburg, Germany; Division of Nuclear Medicine, Department of Diagnostic and Interventional Radiology and Nuclear Medicine, Goethe University Frankfurt, University Hospital, Germany., Molecular Imaging and Therapeutics, Department of Radiology, University of North Carolina, Chapel Hill, NC, USA., University Clinic for Nuclear Medicine, Inselspital, University Hospital of Bern, Bern, Switzerland. Electronic address: .